Startup brief
British Founders Clinch Growth Millions for Humanoids and Healthcare AI
A London robotics developer hits unicorn status to pioneer wheeled industrial automation, while a Cambridge healthtech scaleup raises £14.2M to help clear NHS backlogs.
Startup
Europe now has a physical robotics champion — securing deep manufacturing partnerships with Bosch and Schaeffler could give the London startup a critical supply-chain edge over US and Chinese rivals.
BackgroundHumanoid robotics startups are competing globally to automate labor-intensive industries, but European firms have traditionally lagged behind US and Chinese giants in late-stage capital. Unlike bipedal rivals, Humanoid utilizes a wheeled design built for industrial floor environments.
- The Series A round was led by Prime Movers Lab and backed by German industrial giants Bosch and Schaeffler, providing critical manufacturing partnerships that could accelerate commercial production.
- Industrial actuator specialist Schaeffler will supply high-precision components to Humanoid, helping the startup bypass the global supply chain bottlenecks that delay rival bipedal developments.
- Humanoid plans to deploy its first commercial beta systems in late 2026, targeting severe labor shortages in European warehouses and retail sites where human workers are increasingly scarce.
Startup
TidalSense is bypassing slow clinical lung tests with rapid artificial intelligence diagnostics — giving the underfunded NHS an immediate path to clear its massive respiratory backlogs.
BackgroundDiagnosing respiratory diseases like chronic obstructive pulmonary disease (COPD) historically requires spirometry tests that demand forced exhalation and significant clinic time. These complex tests have created massive, post-pandemic patient backlogs within the National Health Service.
- The funding round was led by Cross-Border Impact Ventures with participation from BGF, raising TidalSense's total capital to $40M to accelerate clinical trials.
- The company's CE-marked handheld device captures carbon dioxide waveforms from 75 seconds of normal breathing, delivering a reliable COPD diagnosis in under 5 minutes to bypass slow clinic tests.
- TidalSense will use the capital to expand clinical deployments across the UK and Europe, while preparing regulatory filings to enter the massive US healthcare market next year.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.